Payment overview · 2025
General Payments
$528.15
23 reported records · 6 companies
Healthcare provider profile · identity verified
Wendee A Amero, NP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DERRY, NH · NPI 1568130565
Verified facts
What the public records show
CMS Open Payments records show Wendee A Amero, NP-BC received $528.15 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $312.52 | 59.2% | 18 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$120.70 | 22.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.15 | 5.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.13 | 4.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.88 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.77 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $528.15 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $230.48 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $155.26 | 8 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $120.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.64 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 345 | 97 |
| Lisinopril | Lisinopril | 264 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 67 |
| Losartan Potassium | Losartan Potassium | 224 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 43 |
| Omeprazole | Omeprazole | 158 | 43 |
| Simvastatin | Simvastatin | 122 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 33 |
| Alprazolam | Alprazolam | 116 | 21 |
| Sertraline Hcl | Sertraline Hcl | 107 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 45 |
| Gabapentin | Gabapentin | 106 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 33 |
| Metformin Hcl | Metformin Hcl | 98 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 28 |
| Lorazepam | Lorazepam | 81 | 30 |
| Trazodone Hcl | Trazodone Hcl | 80 | 25 |
| Tramadol Hcl | Tramadol Hcl | 75 | 24 |
| Montelukast Sodium | Montelukast Sodium | 73 | 23 |
| Metformin Hcl Er | Metformin Hcl | 69 | 19 |
| Furosemide | Furosemide | 59 | 20 |
| Clonazepam | Clonazepam | 56 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 15 |
| Synthroid | Levothyroxine Sodium | 56 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 13 |
| Eliquis | Apixaban | 53 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Carvedilol | Carvedilol | 45 | 12 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Methylprednisolone | Methylprednisolone | 42 | 37 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 13 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 20 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Atenolol | Atenolol | 30 | 11 |
| Famotidine | Famotidine | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 15 |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Propranolol Hcl | Propranolol Hcl | 29 | 14 |
| Prednisone | Prednisone | 28 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $528.15 · 23 records | ABBVIE INC. | AIRSUPRA, JARDIANCE, OTEZLA, QULIPTA, REPATHA, SYMPLICITY G3, UBRELVY, VRAYLAR, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error